Alternatively, sensitivity to mTOR inhibition could be due to the endothelial origin of EHE, as other vascular sarcomas and vascular malformations have elevated mTOR signaling [83,106,107,108,109,110] and show sensitivity to Sirolimus [91,111,112,113,114,115,116,117,118]. Here, MTOR is linked to vascular sarcoma.